Dr. Schwartz CEO of SKLN and Dr. Garvin with CytoBioscience Discuss Positive Results of a Merger in Progress with Their Two Companies
Eagan, MN , Aug. 16, 2017 (GLOBE NEWSWIRE) -- Dr. Schwartz CEO of SKLN and Dr. Garvin with CytoBioscience Discuss Positive Results of a Merger in Progress with Their Two Companies
Eagan, MN (UPTICK Newswire – August 16, 2017) - CEO Dr. Carl Schwartz of Skyline Medical Inc. (NASDAQ: SKLN), a medical technology company, and Dr. Jim Garvin with CytoBioscience, a company in the human cell research on new therapeutic drug development, were both interviewed on the Uptick Network Stock Day Podcast with host Everett Jolly. Dr. Schwartz and Dr. Garvin both discuss positive outcomes for a merger involving the two companies and when this transaction could be completed. Both companies speak on their partnership strategies, what both organizations bring to the table for one another and what the companies are planning together with this merger. Dr. Garvin briefly touches on past company revenues and the future potential for revenue growth while Dr. Schwartz touches bases on high hopes for Skyline Medical’s fourth quarter.
In a closing statement Dr. Jim Garvin states, “We have risked a fair amount of our time and good fortune in being able to build this company and get it into a position where we can get into a relationship like Skyline. My team, myself, my investors really believe in this product set, they believe in this transaction and they believe in Skyline,” Dr. Garvin continues, “I think there’s a real opportunity here for investors to come along to what I think is going to be a really wonderful ride and I’m saying this because I believe it with all my heart.”
Dr. Schwartz agrees, “I believe that very much and concur with what Dr. Garvin has said and we think we are in for an exciting ride. CytoBioscience is a wonderful company, it will fit well with Skyline and we both expect substantial growth in the next few years, so keep an eye on us.”
To listen to the interview please click here or the following link: https://upticknewswire.com/iinterview-ceo-paul-danner-of-alliance-mma-inc-nasdaq-amma
About Skyline Medical
Skyline Medical produces a fully automated, patented, FDA-cleared waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S. For additional information, please visit www.skylinemedical.com.
CytoBioscience creates and manufactures devices that represent a convergence of bioscience, nanoscience, microchip development, algorithms and engineering. The company’s devices allow researchers, medical institutions and pharmaceutical companies to better understand how human cells react to medicine. CytoBioscience has a world-renown scientific and technical staff, collaborative partnerships with leading pharmaceutical companies and strategic alliances with key groups and academic institutions, and its technology is used exclusively by the FDA. The company was founded in Germany and moved its headquarters and manufacturing to San Antonio, Texas in 2015. For additional information, please visit www.cytobioscience.com.
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, risks related to the proposed merger, including the fact that we may not complete the merger; we do not have complete information about CytoBioscience, including audited financial statements; the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Company’s and CytoBioscience’s existing businesses, distraction of management and diversion of resources; delay in completion of the merger may significantly reduce the expected benefits; and the market price of the Company’s common stock may decline as a result of the merger. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.
Skyline Medical Inc.
Dr. Carl Schwartz
James R. Garvin, PhD
Source: Uptick Newswire
CONTACT: Company Contact Skyline Medical Inc. Dr. Carl Schwartz 651-389-4800 CytoBiosciences James R. Garvin, PhD 210-767-2727
Looking for special service?
Don't spend time on search!
Get applications from providers For Free